ImmunityBio (IBRX) Convertible Debt (2022 - 2026)

ImmunityBio (IBRX) has 5 years of Convertible Debt data on file, last reported at $678.4 million in Q1 2026.

• On a quarterly basis, Convertible Debt rose 39.67% year-over-year to $678.4 million in Q1 2026; TTM through Mar 2026 was $678.4 million, a 39.67% increase from a year earlier, with the FY2025 full-year figure at $477.1 million, up 3.29% from the prior year.
• Convertible Debt for Q1 2026 stood at $678.4 million, up from $477.1 million in the prior quarter.
• Over the last five years, Convertible Debt for IBRX reached as high as $678.4 million in Q1 2026 and fell as low as $165.3 million in Q3 2023.
• Historically, Convertible Debt has averaged $467.9 million across 5 years, with a median of $492.1 million in 2025.
• On a YoY basis, Convertible Debt climbed as much as 255.73% in 2024 and fell as far as 19.95% in 2024.
• Year by year, Convertible Debt stood at $241.3 million in 2022, then soared by 139.13% to $577.0 million in 2023, then fell by 19.95% to $461.9 million in 2024, then increased by 3.29% to $477.1 million in 2025, then jumped by 42.19% to $678.4 million in 2026.
• Per Business Quant data, the three most recent Convertible Debt figures were $678.4 million in Q1 2026, $477.1 million in Q4 2025, and $500.8 million in Q3 2025.